Abstract 3139: The novel peptide drug conjugate AVA6103 is a FAP-enabled pre|CISION® medicine which targets exatecan, a topoisomerase I inhibitor, to the tumor microenvironment following FAP cleavage
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Curtis Rink, Tom Clough, Ellen Watts, Folake Orafidiya, Marine Houee, Cindy Tong, Victoria Juskaite, Michelle Morrow, David Jones, Francis Wilson
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409643427